Podcasts about Oncology

How do we find the "heart" of survivorship? In this 2025 recap of Navigating Cancer TOGETHER, we explore the most impactful cancer survivor stories of the year and share essential support for caregivers and patients. Host Talaya Dendy reflects on a landmark year for the show, providing a vulnerable 2025 cancer recap that balances professional milestones with her own personal 14-year health and survivorship journey.Whether you are navigating life after cancer or are currently in the thick of treatment, this episode offers a roadmap for the road ahead. We dive into the most-listened-to stories of the year, from prostate cancer awareness and men's health to the "Choosing Flat" movement and why these patient and survivor-led voices are the true heartbeat of the cancer community.Stop navigating alone. Join us!✨Episode Highlights:00:07:11 The Top Stories of 2025: Prostate Cancer Awareness & Choosing Flat00:10:17 Breaking the Silence: The Importance of Black Men's Voices in Cancer00:16:21 The 4:00 AM "Insomnia Club"00:24:23 Talaya's Favorite Moment: "What's at the Heart of Survivorship?00:32:14 14 Years NED & "Graduating" OncologyTranscript: https://bit.ly/podscript179Playlist: https://podcast.ausha.co/navigatingcancertogether/playlist/best-of-2025Connect & Engage with Talaya: https://solo.to/cancerdoula

The most anticipated annual tradition on Out of Patients returns with the 2025 Holiday Podcast Spectacular starring Matthew's twins Koby and Hannah. Now 15 and a half and deep into sophomore year, the twins deliver another unfiltered year end recap that longtime listeners wait for every December. What began as a novelty in 2018 has become a time capsule of adolescence, parenting, and how fast childhood burns off.This year's recap covers real moments from 2025 A subway ride home with a bloodied face after running full speed into that tree that grows in Brooklyn. Broadway obsessions fueled by James Madison High School's Roundabout Youth Ensemble access, including Chess, & Juliet, Good Night and Good Luck, and Pirates of Penzance holding court on Broadway. A Disneylanmd trip where the Millennium Falcon triggered a full system reboot. A New York Auto Show pilgrimage capped by a Bugatti sighting. All the things.The twins talk school pressure, AP classes, learner permit anxiety, pop culture fixation, musical theater devotion, and the strange clarity that comes with turning 15. The humor stays sharp, the details stay specific, and the passage of time stays undefeated. This episode lands where the show works best: family, honesty, and letting young people speak for themselves.FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Men often don't think of themselves as having breasts. For men, it's their chest or their “pecs.” So it may come as a surprise to learn men are at risk of breast cancer. The fact is men have breast tissue and can get breast cancer. In the U.S., less than 1% of all cases occur in men, but it does happen. Today we are joined by Jake Messier, a man living with metastatic breast cancer, after being misdiagnosed twice and finally learning in August 2024 that it had advanced. Jake openly shares his story across active social media platforms and is dedicated to spreading awareness of male breast cancer, as well as the distinct mental and physical health struggles that go largely unaddressed when a man is navigating what is typically seen as a woman's disease.

Start making $150k - $200k+ in your first year of medical sales. Stop chasing crowded "old school" roles like Orthopedics and Spine. The real money—and the life-saving innovation—is in Oncology and Specialty Pharma. Today, I reveal the exact blueprint to reinvent your career and break into the most lucrative sector of healthcare. Whether you're a nurse, a teacher, or stuck in a "middle-class mindset," this episode breaks down why your background doesn't matter. Only your preparation does.I share my personal journey from a non-profit minister making $70k to a high-level oncology rep, and explain why "casual advice" from friends will get you rejected. If you want to master the interview, crush your clinical knowledge, and build a 6-figure life, this is the masterclass you need.WHAT YOU WILL LEARN IN THIS EPISODE:- The "Gold Rush" Shift: Why you should ignore Orthopedics and focus entirely on Oncology, Diagnostics, and Genetic Testing.- The 3 Essential Mindset Shifts: How to move from "winging it" to becoming an obsessively prepared candidate.- Real Success Stories: How Kanika (immigrant to Dallas), Sydney (nurse), and others went from zero experience to $200k roles.- The "Ride-Along" Trap: Why you need a brutal coach, not a nice mentor.- The HEART Framework: The 5 character traits (Humility, Energy, Active Listening, Resilience, Trust) that hiring managers look for.- Confidence vs. Arrogance: How to show "grit" without sounding like a jerk.- Daily Habits of Top 1% Earners: The 5 AM club, the "20 LinkedIn adds" rule, and why your degree (MBA) has a lower ROI than coaching.- The Michael Jordan Rule: Why even the greatest of all time hired coaches for their specific weaknesses.TIMESTAMPS00:00 - Introduction: The Program Focus (Oncology vs. Orthopedics)01:34 - Dave's Story: Reinventing Career from Ministry to Medical Sales03:44 - Success Stories: How Nurses & Immigrants Got Hired (Kanika, Sydney)06:47 - Mindset Shift #1: Be Coachable (Why Friends Can't Help You)09:20 - Mastering Virtual Interviews (Lighting, Camera & Background)10:32 - Mindset Shift #2: Be Curious (Understanding Clinical Trials & FDA)12:32 - Salary Reality: Device Associate ($80k) vs. Oncology ($155k+)13:55 - Mindset Shift #3: Collaboration (Working with MSLs & Nurse Navigators)16:28 - Confidence vs. Arrogance (The "Grit" Trap)18:02 - The H.E.A.R.T. Framework (Humility, Energy, Listening, Resilience, Trust)19:00 - Daily Habits: 5 AM Wake-ups, LinkedIn Strategy & Handling Rejection20:00 - The"Middle Class Mindset" Trap: Why Degrees Have Low ROI22:25 - Using AI for Resumes Without Sounding Like a Robot25:55 - The "Why": Patient Outcomes & Life-Extending Impact29:35 - The 3 Questions You Must Ask Yourself31:01 - The Michael Jordan Analogy: Why Even the Best Hire Coaches.ABOUT MEDICAL SALES U: Medical Sales U is the premier training program for professionals looking to break into high-paying careers in Medical Device, Pharmaceutical, and Genetic Testing sales. We turn "outsiders" into top 1% candidates.CONNECT WITH US: Learn more about coaching and career support at medicalsalesu.com/#MedicalSales #OncologySales #CareerPivot #SalesCoaching #HighIncomeSkills #DaveSterrett #MedicalSalesYou #InterviewTips #SalesJobs #PharmaceuticalSales

Are you up to date on the evolving treatment landscape for HER2-mutated non-small cell lung cancer (NSCLC)? Do you know the role of novel targeted therapies? Credit available for this activity expires: 12/24/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/precision-oncology-her2-mutated-nsclc-strategies-today-and-2025a100105r?ecd=bdc_podcast_libsyn_mscpedu

Behind the Knife ABSITE 2026 – Up-to-date and high yield learning to help you DOMINATE the exam. Don't forget to check out our ABSITE Podcast Companion Book available on Amazon: https://www.amazon.com/Behind-Knife-ABSITE-Podcast-Companion/dp/B0CLDQWZG3/ref=monarch_sidesheet Be sure to check out our free study aid, which includes all 32 review episodes, brief written summaries, high yield images, and flash cards. Simply create an account on our iOS or Android app or on our website and you will find the entire course in your Library.  Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049 Google Play App Store: https://play.google.com/store/apps/details?id=com.btk.app Behind the Knife would like to sincerely thank Medtronic for sponsoring the entire 2026 ABSITE podcast series.  Medtronic has a rich history of supporting surgical education, and we couldn't be happier that they chose to partner with Behind the Knife.  Learn more at https://www.medtronic.com/en-us/index.html If you like the work that Behind the Knife is doing, please leave us a review wherever you listen to podcasts.   Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   Check out our recent episodes here: https://behindtheknife.org/listen Behind the Knife Premium: General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-review Trauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlas Dominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkship Dominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotation Vascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-review Colorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-review Surgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-review Cardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-review Behind the Knife in Español - repaso para el examen de certificación en cirugía general: https://app.behindtheknife.org/premium/repaso-para-el-examen-de-certificaci-n-en-cirug-a-general

In this week's episode, Blood editor Dr. James Griffin interviews authors Drs. Vincent Muczynski and Mark Geyer on their latest research published in Blood. Dr. Muczynski's research asks if there could there be a better gene than the factor VIII (FVIII) gene to transfer for curative treatment of hemophilia A? Dr. Geyer then explores CAR T cells armed with interleukin-18 (IL-18) secretion that target CD371, a transmembrane glycoprotein with high expression on AML and leukemia-initiating cells. Both studies explore finding novel targets for these powerful treatment modalities. Featured Articles:Alternative AAV gene therapy for hemophilia A using expression of Bi8, a novel single-chain FVIII-mimetic antibodyCD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia

Jason Gilley walked into adulthood with a fastball, a college roster spot, and a head of curls that deserved its own agent. Cancer crashed that party and took him on a tour of chemo chairs, pediatric wards, metal taste, numb legs, PTSD, and the kind of late night panic that rewires a kid before he even knows who he is.I sat with him in the studio and heard a story I know in my bones. He grew up fast. He learned how to stare down mortality at nineteen. He found anchors in baseball, therapy, and the strange friendships cancer hands you when it tears your plans apart. He owns the fear and the humor without slogans or shortcuts. Listeners will meet a young man who refuses to let cancer shrink his world. He fights for the life he wants. He names the truth without apology. He reminds us that survivorship stays messy and sacred at the same time. This conversation will stay with you.RELATED LINKS• Jason Gilley on IG• Athletek Baseball Podcast• EMDR information• Children's Healthcare of AtlantaFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Listen to JCO's Art of Oncology article, "Final Silence" by Dr. Ju Won Kim, who is an Assistant Professor at Korea University College of Medicine, Medical Oncology. The article is followed by an interview with Kim and host Dr. Mikkael Sekeres. Dr Kim explores the burden of silence when caring for dying patients. TRANSCRIPT Narrator: Final Silence, by Ju Won Kim  Dr. Mikkael Sekeres: Welcome back to JCO's Cancer Stories: The Art of Oncology. This ASCO podcast features intimate narratives and perspectives from authors exploring their experiences in oncology. I'm your host, Mikkael Sekeres. I am a Professor of Medicine and Chief of the Division of Hematology at the Sylvester Comprehensive Cancer Center, University of Miami. We are so thrilled to have joining us today, Dr. Ju Won Kim. She is Assistant Professor at Korea University College of Medicine, and she is here to discuss her Journal of Clinical Oncology article, "Final Silence." Ju Won, thank you for contributing to the Journal of Clinical Oncology and for joining us today to discuss your article. Dr. Ju Won Kim: Hello, Mikkael. It's really nice to be here. Thanks so much for inviting me. Dr. Mikkael Sekeres: It's so nice to have you here today also. Thank you for also taking time so late in the evening because our time difference is so huge. Dr. Ju Won Kim: Yeah, it's not that late. It's 9 o'clock in Seoul. 9:00 PM. Dr. Mikkael Sekeres: I wonder if I could start by asking you if you can tell us about yourself. Could you walk us through your career so far? Dr. Ju Won Kim: Yes. I am Ju Won Kim from Korea University in Seoul. I was born and also raised here and never really left from Seoul. I did my residency in internal medicine and fellowship in oncology at the same hospital, and now I'm an assistant professor there. So you could say I've spent my whole life on the same campus, just moving from one side of the hallway to another. Dr. Mikkael Sekeres: That's a beautiful way of describing it. Is that common in Korea for somebody to remain at the same institution for training and then to continue through your career? Dr. Ju Won Kim: It used to be common about a decade ago, but nowadays it is not that common. Most of my colleagues are from another campus or another hospital. Dr. Mikkael Sekeres: Well, I'm so curious, what is a typical week like for you? How many days do you spend seeing patients and how much time do you spend doing research or writing or have other responsibilities? Dr. Ju Won Kim: Usually, I spend four times for my outpatient clinic, but in Korea, there are so many cancer patients and so little number of medical oncologists. I usually treat so many patients in one clinic, like maybe 20 to 30 in one time. Dr. Mikkael Sekeres: Wow. Dr. Ju Won Kim: Yeah, that's a burden. Most of the time I spend treating my patients, and rest of them I use to spend for my research with my lab students, and maybe with my colleagues, and I have to write something like documents or some kind of medical articles. That is about 10 or 20% of my working time, I think. Dr. Mikkael Sekeres: Okay, okay. That makes sense. So, and do you specialize within oncology, or do you see any person who has cancer? Dr. Ju Won Kim: I'm a medical oncologist, and I used to treat breast cancer or biliary pancreatic cancer or some kind of liver cancer or rare cancer, maybe, also. Dr. Mikkael Sekeres: Okay, okay. It's such a long trip. Are you able to make it to the ASCO Annual Meeting in Chicago? Dr. Ju Won Kim: Actually, I've been Chicago for ASCO meeting just one time in this year. Actually, I gave birth to my son in March, and I was in the long vacation for my birth, and the last part of my birth vacation, I went to Chicago to participate in ASCO. It was a really good time. Dr. Mikkael Sekeres: Oh, fantastic. That's great. How about your own story as a writer? How long have you been writing narrative pieces and when did you start? Dr. Ju Won Kim: Actually, I've always thought of myself more as a reader than a writer. Reading was my comfort zone from childhood. Then I started a small book club with friends about 10 years ago, and we began writing short reflections after each meeting. That's how writing slowly became part of my routine. When reading feels heavy, I write. When writing feels tiring, I read. It's a rhythm that keeps me balanced. At first, it was only academic writing like medical articles, but a few years ago, I challenged myself to post one short reflection a month on my Instagram, usually a quote from a book and a few sentences on why it mattered to me. It was my life about writing. Dr. Mikkael Sekeres: That is really remarkable. So, did you take any formal writing classes at university? Dr. Ju Won Kim: Not really. It was just a hobby of my own. Dr. Mikkael Sekeres: It always impresses me when people come into writing organically like this, where they just discover it and start and don't have formal teaching because your writing is very, very good. Dr. Ju Won Kim: Oh, thank you. Dr. Mikkael Sekeres: And how do you find the time to read and write when you have a busy career, academic career, and you have a child? Dr. Ju Won Kim: It was my old routine that I used to read it before going to bed, from my bedside with a small light, I used to read some novels and get to sleep easily. But after I started to work as a medical oncologist, it was a very busy job as you know. I used to sleep more and not have time for reading. I try to read more when I get some free time. Dr. Mikkael Sekeres: I love how you talk about alternating reading and writing and how when one gets too heavy, you go to the other, and then you switch back. One of the most common pieces of advice I've heard from writers is to read more. Dr. Ju Won Kim: Yeah. Dr. Mikkael Sekeres: You can see how other people put thoughts together and the cadence of their writing, and also it inspires your mind to develop new ideas for writing. Dr. Ju Won Kim: Actually, the new idea also comes from the book, I think, when I came into a new book and the idea bangs up with me, so I started to write and that's an easy way to have some idea about writing. Dr. Mikkael Sekeres: I'm always impressed by people who are facile with languages and bilingual or trilingual. I think I'm unfortunately a hopeless monoglot. Dr. Ju Won Kim: Maybe you can try Korean. Dr. Mikkael Sekeres: I'd be embarrassed to even attempt it. When you read, do you read in Korean or do you read in English or other languages? Dr. Ju Won Kim: Definitely in Korean. Dr. Mikkael Sekeres: Okay, okay. And when do you find the space to write? Do you need to be alone at home in a special room or at a special desk, or do you write at work, or do you just find any time to write? Dr. Ju Won Kim: I usually don't have much time on my own because I have my baby now and some family gathers frequently. So, I always write every free time I'm trying to, any short free time in my work maybe. Dr. Mikkael Sekeres: If you feel comfortable doing so - this is a very heavy piece, and a lot of us have dealt with deaths of our own patients, of course, we see this unfortunately commonly in oncology, but many of us, myself included, have also dealt with patients or their family members who've committed suicide - can you tell us what prompted you to write this piece? Dr. Ju Won Kim: As an oncologist treating biliary and pancreatic cancers, I've witnessed many deaths, as you know. Most fade with time because I treat so many patients, but just one family stayed with me, I think. It was early in my career, just months after I started this specialty, and even 5 years later, I still think about them, the family I wrote about in the "Final Silence." The story eventually became the piece I wrote. Dr. Mikkael Sekeres: And what is it about them that caused you to think about them so much even years later? Dr. Ju Won Kim: I'm not sure. That's the only experience I came into someone's suicide so closely in my life, I think, and also it happened in my very early career. That's the impact. Dr. Mikkael Sekeres: It is amazing how certain patients stick with us even years or decades later, particularly when they're tied to an emotional response to illness, and that can be our patients' emotional response or our own. Can you talk some about Korean culture and how cancer is viewed? Is it discussed openly? Dr. Ju Won Kim: In Korea, death is still a quiet topic. Cancer equals death in many people's minds, and death equals grief. Even today, some families ask doctors not to tell their patients about the diagnosis, but Korea is aging so fast, so I see more older patients now, but culturally, we are still learning how to talk about dying openly. That's the big problem as a medical oncologist, especially treating biliary and pancreatic cancers. Dr. Mikkael Sekeres: I can just imagine. When you first meet a patient and their family is in the room, do you tell them that they have cancer, or do you need to check in with the family and with the patient how much they know about their diagnosis first? Dr. Ju Won Kim: Actually, I usually try to tell them there is a cancer, which can never be treated perfectly, because I used to treat patients with stage four, which is incurable, but I'm not sure is it okay to tell them that your life is about 3 months or 6 months or 1 year. It is not that okay for the Korean patients, especially the first time when they meet me in the clinic. I try to tell them about the truth just a few times later. Dr. Mikkael Sekeres: I think that's common. I think we do that in the United States also. We may not mention a number to patients during that very first meeting because when you're talking to somebody and once you mention that number, often people will shut down. They won't hear anything else that you say. And you need to build up a relationship and some trust with somebody and also get the sense how much they want to know about their cancer and their prognosis before entering that conversation. I've certainly had instances when I'm in a room with a patient, and that patient's spouse or children, and someone else in the room will say, "How long does Dad have to live?" And I've turned to my patient, "Dad", and said, "Is this a number that you want to know?" And the patient has said, "No, I don't." Dr. Ju Won Kim: Yeah, that happens. Dr. Mikkael Sekeres: So sometimes we have to be careful and check in and remind ourselves in the high emotions around a cancer diagnosis that our first responsibility is always to our patient and what they want to know about their diagnosis and their prognosis. Dr. Ju Won Kim: Do you have any opposite cases where patients really want to know the numbers? Dr. Mikkael Sekeres: Yeah, I do. And, you know, you can almost predict who that's going to be depending on what they did during their lives. Dr. Ju Won Kim: Yes. Dr. Mikkael Sekeres: So I have patients who are engineers or who have a math-based career like they're accountants and they'll come in and they write every number down and they want to know the number about their prognosis. I have other patients who are English professors and they want descriptively to know what the prognosis is but maybe don't want a number. So... Dr. Ju Won Kim: I think most Koreans want the number, the specific number. Yeah. Dr. Mikkael Sekeres: I'm curious, is cancer in a father or a son dealt with differently than cancer in a mother or a daughter? Dr. Ju Won Kim: I don't think there's much difference between sons and daughters, or maybe moms and dad, because every child is very precious in Korea now, but between husband and wives, I think the dynamic stands out. People often say when a husband gets cancer, the wife becomes his main caregiver, but when the wife gets cancer, sometimes the husband disappears. I've heard that from my colleagues, though not often in my own clinic. Now, what I do see is many middle-aged women who have been diagnosed with breast cancer, women coming to treatment alone, strong and very independent. Dr. Mikkael Sekeres: Interesting. So I was going to follow up by asking if you've seen that in your own clinic. Have you seen- is it more likely that your female patients who have a cancer diagnosis come to clinic alone but the male patients come with their spouse and with family support? Dr. Ju Won Kim: Yeah, it is not just because of their sex, but most of the breast cancer patients who are female are in good condition, but biliary pancreatic cancer male patients have very poor condition, so... Dr. Mikkael Sekeres: Ah... Dr. Ju Won Kim: Maybe, I think that's the problem. Dr. Mikkael Sekeres: Interesting. The part of your essay in which you describe the attempted suicide of your patient's daughter is absolutely chilling. How did that affect you? Have you ever had a patient attempt suicide before? Dr. Ju Won Kim: Yes, the event I wrote in my essay was extremely shocking for me, but it's the only experience I have. It wasn't my patient, but I've heard a few cases where someone in the hospital tried to take their own life. I haven't had that happen directly, but I've seen patients fall into deep depression or break down in tears. In those moments, I always suggest psychiatry nowadays. That used to be taboo in here, but the stigma is fading, and many patients actually feel better afterwards. I also check in with close family members because their mental state affects the patients, too. It's something I hope never to experience again. Dr. Mikkael Sekeres: It's so unsettling when that happens, and as I mentioned, I've had a patient who took his own life, and you go back and back and back to it to wonder if there's something you could have done to intervene quicker or to get that psychosocial support in place to help that patient so that you avoid it in the future. And, you know, you protect your patients and yourself. Dr. Ju Won Kim: Yeah, I try to. Dr. Mikkael Sekeres: Speaking of protecting, you write, and I'm going to quote you to you, "I told myself I was protecting her, that to burden her in her final hours with such unthinkable news would be cruel. But a deeper truth is that I was protecting myself. I didn't know how to say it. I didn't know how to bear the weight of her devastation on top of my own shock and helplessness, so I avoided it." Do we owe it to ourselves sometimes to protect ourselves from the pain we sometimes impart to our patients? Dr. Ju Won Kim: That reflection came from realizing how doctors sometimes say we are protecting patients from pain, but really, we are protecting ourselves, I think. It's human. We can't hold every piece of suffering we see. Setting emotional boundaries isn't weakness. It's survival. What matters is recognizing when it's self-protection and being honest about it later. Dr. Mikkael Sekeres: Well, I think something that really helps with that is being able to talk to our colleagues about times when this happens and recognize we're in a shared experience and that we have the support of our colleagues, and they recognize how hard it is to be the bearer of bad news to other people and to bring pain to them sometimes. Dr. Ju Won Kim: That really works. Dr. Mikkael Sekeres: Dr. Ju Won Kim, it has been such a pleasure having you on this show. Dr. Kim has written just a fabulous essay called "Final Silence" for JCO Art of Oncology. Thank you so much for sharing your article with us and for joining us today. Dr. Ju Won Kim: Yeah, thank you so much for the conversation. It was a pleasure talking with you. Dr. Mikkael Sekeres: If you've enjoyed this episode, consider sharing it with a friend or a colleague or leave us a review. Your feedback and support helps us continue to have these important conversations. If you're looking for more episodes and context, follow our show on Apple, Spotify, or wherever you listen and explore more from ASCO at asco.org/podcasts. Until next time, this has been Mikkael Sekeres for Cancer Stories. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Show Notes: Like, share and subscribe so you never miss an episode and leave a rating or review. Guest Bio:Dr Ju Won Kim is an Assistant Professor at Korea University College of Medicine, Medical Oncology.

This week, Bobbi Conner talks with MUSC's Dr. Katie Schmitt about oncology physical therapy.

Send us a textWelcome back to The Oncology Journal Club podcast — our favourite episode of the year!Hosted by Professor Craig Underhill, Dr Kate Clarke and Professor Christopher Jackson.The team reflect on the achievements of 2025, highlighting key developments, initiatives and papers that have made — and will continue to make — a real impact on clinical practice. As CJ says, it's a privilege to work in what is the “single most innovative and thoughtful field in all of medicine” — and we are indeed lucky to have our brains tickled every month by this wonderful podcast.And of course, it wouldn't be OJC without some laughs and a few naughty jokes — and this year, we even have the inaugural OJC Christmas haiku!Thank you for listening. We hope you enjoy the final episode of The Oncology Journal Club for 2025.Visit oncologynetwork.com.au for Show Notes and more information. Proudly produced by the team at the Oncology Network

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Andrea Necchi, MD Presented at the 2025 ESMO Congress, the IMvigor011 phase 3 trial evaluated a ctDNA-guided strategy for administering adjuvant atezolizumab in patients with muscle-invasive bladder cancer (MIBC) following radical cystectomy. Patients with high-risk pathological features were monitored using a personalized, tumor-informed ctDNA assay; those testing positive for ctDNA were randomized to receive atezolizumab or placebo, while ctDNA-negative patients continued surveillance without treatment. The trial demonstrated significant improvements in both disease-free and overall survival in the atezolizumab group along with favorable outcomes among ctDNA-negative patients, suggesting many may safely avoid overtreatment. Joining Dr. Charles Turck to unpack the study results and how they highlight ctDNA's role in guiding personalized therapy is Dr. Andrea Necchi. Not only is he an investigator on this research, but he's also an Associate Professor of Oncology at Vita-Salute San Raffaele University and the Director of Genitourinary Medical Oncology at IRCCS San Raffaele Hospital and Scientific Institute in Milan, Italy.

As we close out the year, we're shining a light on the quiet, powerful work happening every day inside Komen's Patient Care Center. In this special episode, we sit down with two of our remarkable patient navigators — Marcela Orozco and Ladoya Mayfield — to share the biggest impact stories of the year. From helping Spanish-speaking callers break through language barriers to supporting Houston communities facing some of the highest burdens of breast cancer, Marcela and Ladoya bring humanity, hope and heart into the lives of people going through one of their hardest moments.

Are you a nurse or healthcare professional feeling burned out, underpaid, and stuck in a cycle of bureaucracy?Today, I reveal the 3-3-3 Framework: a blueprint specifically designed for bedside nurses who want to break into the high-paying world of Pharmaceutical and Medical Device Sales.If you are tired of missing holidays and hitting a salary ceiling, this episode explains exactly what you actually need to do to land offers like our student Sydney, who went from $68k to a $138k package.IN THIS EPISODE, YOU WILL LEARN:The 3 Reasons to Leave: Why burnout and lack of creativity are signs it's time to pivot.The 3 Barriers: Why relying on your degree and "following orders" kills your chances in sales interviews.The 3 Solutions: How to leverage your clinical edge and tap into the 10,000+ open roles in biotech right now.READY TO LAND YOUR DREAM JOB? Apply to Medical Sales University and learn how we help nurses double their income in 12 weeks: medicalsalesu.com/TIMESTAMPS00:00 - Intro: The shift from Bedside to Sales01:38 - The 3 Reasons healthcare workers are leaving (Burnout & Bureaucracy)03:13 - Why your career growth has stalled04:10 - The 3 Barriers: Why you aren't getting hired yet05:00 - The "Middle Class Mindset" trap (Degree vs. Skills)06:12 - Mindset Shift: From Compliance to Ownership09:18 - The 3 Solutions: How to finally break in10:52 - Success Story: How Sydney landed a $138k Oncology role12:50 - Why mentorship beats doing it aloneABOUT THE HOST: Dave Sterrett is the founder of Medical Sales University, the #1 program helping nurses, PTs, and healthcare professionals break into pharmaceutical and oncology sales.ABOUT MEDICAL SALES U: Medical Sales U is the premier training program for professionals looking to break into high-paying careers in Medical Device, Pharmaceutical, and Genetic Testing sales. We turn "outsiders" into top 1% candidates.CONNECT WITH US:Learn more about coaching and career support at medicalsalesu.com/#MedicalSales #NursingCareer #PharmaSales #NurseBurnout #CareerChange #MedicalDeviceSales #HighPayingJobs #Nurselife

This episode of the collaborative podcast between Oncology on the Go and the American Psychosocial Oncology Society (APOS), hosted by Daniel C. McFarland, DO, features Michelle B. Riba, MD, and focuses on integrating psychosocial care into oncology for clinicians. The discussion emphasizes that psychosocial issues profoundly impact both quality of life and cancer-related outcomes, making their assessment an integral part of care, not merely ancillary. The distress thermometer was developed by the NCCN in the late 1990s as a 0-to-10 scale, dubbed the "fifth vital sign". The term "distress" was chosen over psychiatric labels to capture the wide array of patient concerns, including pain, fatigue, sleep, spiritual, practical, and family issues. Distress screening is now mandated at regular appointments in all cancer centers in the US. Clinicians are encouraged to screen for more specific issues like depression (linked to poor adherence and survival), anxiety (which can impede treatment adherence), and substance use. Oncologists are the doctors most able to consider a patient's totality of symptoms, and their role is integral to supporting psychosocial referrals. To address the practical delivery of care, the collaborative care model is being advocated as a public health, population-based approach. Key components include: Use of a standardized screening tool. Management by a dedicated care manager. Weekly consultation between the care manager and a consultant psychiatrist for triage and treatment advice. The model allows oncologists to bill for care and learn more about these issues while ensuring patients receive evidence-based treatments. The clinicians concluded that fundamentally, mental health needs to be aligned alongside cancer care. McFarland is the director of the Psycho-Oncology Program at Wilmot Cancer Center and a medical oncologist who specializes in head, neck, and lung cancer, in addition to being the psycho-oncology editorial advisory board member for the journal ONCOLOGY. Riba is director of the PsychOncology Program, a clinical professor, and the associate chair for Integrated Medical and Psychiatric Services in the Department of Psychiatry at the University of Michigan Rogel Cancer Center, and psycho-oncology editorial advisory board member for the journal ONCOLOGY.

In this episode of the Veterinary Cancer Pioneers Podcast, host Dr. Rachel Venable is joined by Dr. Doug Thamm, Stuart Presidential Chair in Oncology and Director of Clinical Research at the Colorado State University Flint Animal Cancer Center. Dr. Thamm discusses how naturally occurring cancers in dogs are advancing cancer drug development and informing treatment strategies in both veterinary and human medicine. He shares real-world examples of comparative oncology in action and the role clinical trials play in bringing new therapies to patients. The conversation also explores the challenges of oncology drug development, regulatory pathways, and emerging areas such as biologics, genomic sequencing, and AI-driven tools—offering a clear-eyed view of where veterinary oncology is headed.

What is a call? How does a person know if God is calling them to mission service? Join in a discussion as these and other questions are addressed.

Klinisch Relevant ist Dein Wissenspartner für das Gesundheitswesen. Drei mal pro Woche, nämlich dienstags, donnerstags und samstags, versorgen wir Dich mit unserem Podcast und liefern Dir Fachwissen für Deine klinische Praxis. Weitere Infos findest Du unter https://klinisch-relevant.de

Dr. Marissa Russo trained to become a cancer biologist. She spent four years studying one of the deadliest brain tumors in adults and built her entire research career around a simple, urgent goal: open her own lab and improve the odds for patients with almost no shot at survival. In 2024 she applied for an F31 diversity grant through the NIH. The reviewers liked her work. Her resubmission was strong. Then the grant system started glitching. Dates vanished. Study sections disappeared. Emails went silent. When she finally reached a program officer, the message was clear: scrub the DEI language, withdraw, and resubmit. She rewrote the application in ten days. It failed. She had to start over. Again. This time with her identity erased.Marissa left the lab. She found new purpose as a science communicator, working at STAT News through the AAAS Mass Media Fellowship. Her story captures what happens when talent collides with institutional sabotage. Not every scientist gets to choose a Plan B. She made hers count.RELATED LINKSMarissa Russo at STAT NewsNIH F31 grant story in STATAAAS Mass Media FellowshipContact Marissa RussoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this week's episode, Blood editor Dr. Laurie Sehn interviews three of the latest Blood authors: Drs. Vijay Sankaran, Ruud Delwel, Françoise Kraeber-Bodere. Two studies on the MECOM gene have been paired in this episode, analyzing new groundwork for potential novel myeloid differentiation therapies via repression of MECOM restoring enhancer mediated CEBPA expression. We'll also hear about the results of CASSIOPET, imaging companion study of the CASSIOPEIA trial, and how achieving negativity in PET before starting maintenance therapy is significant even in patients who still show residual disease in the bone marrow.Featured ArticlesCEBPA repression by MECOM blocks differentiation to drive aggressive leukemiasMECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemia Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed from the CASSIOPEIA trial

This episode is part of the special series Empowered Intimacy: Getting Your Sexy Back After Breast Cancer, where getting your sexy back is about reclaiming confidence, connection, and desire after a breast cancer diagnosis. Melissa Berry sits down with Chelsey Pickthorn, a patient advocate living with stage four triple-negative breast cancer, and Dr. Don Dizon, Chief of Hematology and Oncology at Tufts Medicine and a national leader in sexual health and inclusive cancer care.  They explore the challenges LGBTQ+ individuals face with intimacy, dating, body image, and relationships after a cancer diagnosis. Chelsey shares her experiences navigating disclosure, reconstruction, caregiving, and connection, while Dr. Dizon highlights gaps in healthcare for LGBTQ+ patients.  This honest and hopeful conversation offers guidance, empowerment, and advocacy for inclusive care. Thank you to Lilly, Merck, and Novartis for making this episode possible.  

Send us a textDr. Zeke Emanuel joins Dr. Michael Koren to discuss his new book Eat Your Ice Cream: Six Simple Rules for a Long and Healthy Life. Dr. Emanuel explains how frustrated he is at trendy, influencer-style health advice and how it accentuates intense, short-term "miracle fixes," which are almost always for sale and rarely have medical benefits. He explains his philosophy, and the philosophy of Benjamin Franklin: that, in order to make substantive change, you have to focus on one thing at a time, developing it into a habit. Dr. Emanuel also explains the title of his book, that one of the largest and most important factors in health is social well-being.Preorder Dr. Emanuel's book here: https://www.barnesandnoble.com/w/eat-your-ice-cream-ezekiel-j-emanuel-md/1147402755Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant updates that are shaping the future of healthcare, patient care, and drug development.The U.S. Food and Drug Administration has been particularly active recently, granting Johnson & Johnson a National Priority Review Voucher for its multiple myeloma drug combination. This move highlights the importance of J&J's treatment in addressing unmet needs within oncology, a field continuously striving for innovative solutions. These vouchers expedite the review process, reflecting a broader commitment to accelerating the availability of critical therapies for patients who need them most.Continuing with regulatory advancements, AstraZeneca and Daiichi Sankyo's Enhertu, in combination with Roche's Perjeta, has gained FDA approval as a first-line treatment for unresectable or metastatic HER2-positive breast cancer. This breakthrough is supported by late-stage study results demonstrating a 44% reduction in disease progression or death compared to standard care. The approval signifies not only progress in breast cancer therapeutics but also underscores the potential benefits of strategic collaborations in drug development. Such partnerships are increasingly vital as they aim to optimize therapeutic efficacy through shared expertise and resources.In contrast to these advancements, Pfizer is facing financial recalibrations with projected revenues for 2026 estimated to decline due to diminishing COVID-19 vaccine sales and patent expirations. This situation reflects broader industry challenges as companies navigate post-pandemic market dynamics and patent cliffs, forcing reevaluations of long-term strategies.On another front, Gilead Sciences continues to push boundaries in HIV treatment with a promising single-tablet regimen combining bictegravir and lenacapavir. This innovation targets underserved segments within the HIV market, offering streamlined treatment options that could enhance patient adherence and outcomes significantly.Shifting focus to obesity management, Novo Nordisk's oral semaglutide is emerging as a highly anticipated medication among primary care providers. This trend highlights a growing preference for oral GLP-1 therapies as convenient alternatives to injectable formulations, marking a shift in how obesity—a major public health concern—is managed.The importance of regulatory compliance remains evident as Novo Nordisk received an FDA warning letter concerning manufacturing issues at an Indiana site previously owned by Catalent. This incident underscores the necessity for rigorous quality control in pharmaceutical manufacturing, which can have far-reaching implications on operational dynamics and supply chains.The FDA is also pioneering efforts to incorporate real-world evidence into medical device submissions by opening pathways for extensive deidentified datasets from sources like national cancer registries and electronic health records. This policy shift aims to integrate diverse data sources into the evidentiary foundation for medical device evaluations, potentially fostering innovation within this sector.In line with collaborative efforts, Genentech has partnered with Caris Life Sciences in a multi-year agreement valued at up to $1.1 billion, emphasizing the strategic importance of integrating diagnostic advancements with therapeutic developments to achieve precision medicine goals.Meanwhile, Yarrow Bioscience has acquired an autoimmune thyroid disease drug from China's Gensci, exemplifying a growing trend of cross-border collaborations aimed at leveraging global innovation ecosystems to address diverse therapeutic areas. This acquisition is part of a $1.37 billion deal, reinforcing the globalization of biotech partnerships as companies seek access to novel therapeutics andSupport the show

Scott Capozza and I could have been cloned in a bad lab experiment. Both diagnosed with cancer in our early twenties. Both raised on dial-up and mixtapes. Both now boy-girl twin dads with speech-therapist wives and a lifelong grudge against insurance companies. Scott is the first and only full-time oncology physical therapist at Yale New Haven Health, which means if he catches a cold, cancer rehab in Connecticut flatlines. He's part of a small, stubborn tribe of providers who believe movement belongs in cancer care, not just after it. We talked about sperm banking in the nineties, marathon training during chemo, and what it means to be told you're “otherwise healthy” when your lungs, ears, and fertility disagree. Scott's proof that survivorship is not a finish line. It's an endurance event with no medals, just perspective.RELATED LINKSScott Capozza on LinkedIn: https://www.linkedin.com/in/scott-capozza-a68873257Yale New Haven Health: https://www.ynhh.orgExercising Through Cancer: https://www.exercisingthroughcancer.com/team/scott-capozza-pt-msptProfiles in Survivorship – Yale Medicine: https://medicine.yale.edu/news-article/profiles-in-survivorship-scott-capozzaFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Cancer cases, cancer-related deaths, and survivorship are projected to rise exponentially—yet oncology faces critical workforce shortages. In this episode, CANCER BUZZ speaks with Tristan Blanco, a biology major and fellow in VCU Massey's Cancer-focused Undergraduate Research Experience (CURE) Program, who shares his experience as part of a program designed to scale oncology education and meet the evolving needs of cancer care nationwide. Get behind the scenes of an innovative training model that's preparing the next generation of oncology leaders. "It's one of the smartest ways to address the workforce shortage. We're making sure more students get the chance to discover oncology and have that opportunity." — Tristan Blanco Tristan Blanco Biology major and fellow in the Cancer-focused Undergraduate Research Experience (CURE) Program VCU Massey Comprehensive Cancer Center Richmond, VA Resources: Building a Scalable Model to Train the Next Generation of Oncology Leaders   Combatting Healthcare Workforce Issues with Proven Leadership Skills   Onboarding Experienced Non-Oncology Nurses to Address Staffing Shortages   (Re)Building the Oncology Workforce: ACCC President Dr. Ajayi's 2023-2024 Theme   VCU Massey Comprehensive Cancer Center Spotlight   Addressing Social Determinants of Health through a Medical-Legal Partnership

Host Emily Walsh Martin welcomes Dr. Jim Burns, CEO of Ensoma, to discuss the company's novel technological approach to treating both rare diseases and solid tumor oncology. Dr. Burns provides a detailed overview of Ensoma's platform and its application in their ongoing clinical trials, including the recently announced first patient infusion for chronic granulomatous disease. Learn how this initial trial is set to inform future therapeutic opportunities for indications with high unmet medical need. Music: ‘Bright New Morning’ by Steven O’Brien – released under CC-BY 4.0. https://www.steven-obrien.net/Show your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving deep into the latest breakthroughs, regulatory updates, and industry trends shaping the future of healthcare.Let's start with Johnson & Johnson's recent achievement in precision oncology. They've secured a second FDA approval for Akeega, a combination therapy that merges J&J's Zytiga with GSK's Zejula. This innovative approach targets BRCA2-mutated metastatic castration-sensitive prostate cancer, marking a significant advancement in personalized medicine. This approval not only highlights the progress in tailored treatment strategies but also sets a new benchmark for therapeutic innovation in this particular cancer subset.Moving on to cardiovascular health, Cincinnati's LIB Therapeutics has introduced Lerochol, a third-generation PCSK9 inhibitor designed to lower cholesterol. Unlike its predecessors, Lerochol offers simplified administration, potentially improving patient adherence and outcomes. This approval is part of a broader effort to refine lipid-lowering therapies and better address cardiovascular diseases.In a groundbreaking development for heart rhythm disorders, Milestone Pharmaceuticals has received FDA approval for Cardamyst, a nasal spray that patients can self-administer to manage paroxysmal supraventricular tachycardia (PSVT). This novel treatment option empowers patients with an on-demand solution to control their heart rhythms, significantly enhancing their quality of life.Turning to infectious diseases, Innoviva's Nuzolvence has been approved as a much-needed new treatment for gonorrhea, the first in over three decades following GSK's Blujepa. This marks an essential step forward in combating antibiotic-resistant sexually transmitted infections and highlights the urgency of developing new antimicrobial agents.However, not all ventures have met with success. Argenx recently halted studies of its drug Vyvgart in thyroid eye disease after disappointing trial results. This decision underscores the inherent challenges and risks involved in drug development, particularly when tackling complex autoimmune conditions.Sanofi has faced its own hurdles with Tolebrutinib after experiencing both FDA delays and trial misses in non-relapsing secondary progressive multiple sclerosis. These setbacks emphasize the intricacies of bringing innovative therapies to market and the critical importance of robust clinical trial design and regulatory strategy.Strategic collaborations are also playing a pivotal role in the industry. Adaptive Biotechnologies has partnered with Pfizer to leverage its T-cell receptor discovery technology. Meanwhile, Dren Bio is expanding its collaboration with Sanofi to develop next-generation B-cell depleting therapies for autoimmune diseases. These alliances reflect an increasing trend towards collaborative innovation to harness cutting-edge technologies.Another strategic move comes from Sobi, which has acquired Arthrosi Therapeutics for $950 million to bolster its portfolio with phase 3 gout treatments. This acquisition bypasses traditional IPO routes and showcases evolving deal-making strategies within biopharma.In another exciting development, Kyverna Therapeutics is on the verge of securing the first-in-class CAR-T therapy approval for autoimmune diseases following promising trial results with its CD19 agent. This could herald a new era in autoimmune disease management through cellular therapies.In regulatory news beyond pharmaceuticals, former President Donald Trump signed an executive order establishing a unified federal framework for artificial intelligence (AI). This aims to streamline AI regulation across states and could accelerate AI integration into various sectors, including healthcare.These developments collectively represent pivotal moments in the pharmaceutical and Support the show

We are thrilled to be joined by the co-founder of the Home Edit. She is an Emmy-nominated, NY Times best-selling author, a mom, a wife and a breast cancer survivor - the amazing Clea Shearer. Clea is here to talk about her shocking breast cancer diagnosis at the age of 40, the ongoing reconstruction complications that she has had to endure over the past three years and the unexpected lessons that have come with all of it. Clea's new book is aptly called Cancer is Complicated and she is here to tell us all about how true that statement really is!

Featuring perspectives from Dr Manish A Shah, moderated by Dr Stephen "Fred" Divers, including the following topics:  Highlights and Principles of Management of Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma — Dr Shah (0:00) Case: A man in his early 50s with microsatellite instability-high localized esophageal adenocarcinoma — Dr Mulherin (15:24) Case: A woman in her late 60s with HER2-positive (IHC 3+) and HER2 TKD-mutant metastatic esophageal adenocarcinoma — Dr Warsch (25:34) Case: A woman in her early 70s with HER2-positive (IHC 3+), PD-L1-negative, CLDN18.2-negative metastatic gastric cancer — Dr Mulherin (28:15) Case: A woman in her early 70s with metastatic gastroesophageal junction adenocarcinoma (PD-L1 CPS 15) who begins treatment with FOLFOX/nivolumab and subsequently is found to have CLDN18.2 overexpression — Dr Lamar (35:23) Case: A man in his mid 40s with CLDN18.2-positive metastatic esophageal adenocarcinoma (PD-L1 10%) who receives mFOLFOX6 and zolbetuximab — Dr Yannucci (42:54) CE information and select publications

Featuring perspectives from Dr Gottfried E Konecny, moderated by Dr Stephen "Fred" Divers, including the following topics:  Updates in Ovarian Cancer (OC) 2025 — Dr Konecny (0:00) Case: A woman in her mid 50s with ovarian cancer and a PALB2 germline mutation — Dr Mulherin (17:15) Case: A woman in her early 60s with Stage IVB fallopian tube carcinoma and a BRCA2 germline mutation — Dr Yannucci (26:27) Case: A woman in her mid 60s with OC and a BRCA2 somatic mutation who develops cytopenias on maintenance olaparib — Dr Lamar (35:47) Case: A woman in her early 70s with HER2 IHC 2+, ER-expressing, FOLR1-positive OC — Dr Warsch (42:54) CE information and select publications

Dr Manish A Shah from Weill Cornell Medicine in New York, New York, summarizes the treatment landscape and reviews relevant clinical datasets for patients with gastroesophageal cancers. CME information and select publications here.

Dr Manish A Shah from Weill Cornell Medicine in New York, New York, summarizes the treatment landscape and reviews relevant clinical datasets for patients with gastroesophageal cancers. CME information and select publications here.

Visit ⁠⁠⁠https://longevitybuilders.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠to discover book and The Longevity Builder Health Lab.Episode SummaryFor decades, the standard medical advice for cancer patients was simple: "Rest. Take it easy. Avoid exertion." Today's guest has spent her career proving that advice is not just outdated—it is dangerous.In this episode, Shane Stubbs sits down with Dr. Kathryn Schmitz, the world's leading authority in Exercise Oncology. Dr. Schmitz is the scientist who literally wrote the book on moving through cancer. She spearheaded the "Exercise is Medicine" initiative and has led over $30 million in research funding to prove that exercise changes the biology of cancer.We dive deep into why building a resilient body is your best defense, the specific "Move, Lift, Eat, Sleep, Log" framework, and how resistance training impacts survivorship.PLUS: Stay tuned until the very end for a "Science Spotlight" Bonus Segment. Shane breaks down new research highlighted by Dr. Rhonda Patrick on "Shear Stress"—explaining the physics of how vigorous exercise can mechanically destroy circulating tumor cells and reverse heart aging by 20 years.The Paradigm Shift: Why the old advice to "rest" during cancer treatment is being replaced by a prescription for movement.The Science: Dr. Schmitz's $30M+ research journey and her role in writing the ACSM guidelines for cancer survivors.The Protocol: The "Move, Lift, Eat, Sleep, Log" framework for building a body that can withstand the "Big Four" (Cancer, Heart Disease, Metabolic Dysfunction, Neurodegeneration).Exercise as Medicine: How specific doses of activity can alleviate symptoms, improve chemotherapy tolerance, and boost survival rates.BONUS Segment: The physics of Shear Stress. We discuss Dr. Rhonda Patrick's breakdown of how high-intensity blood flow can kill Circulating Tumor Cells (CTCs) and scrub your arteries.Dr. Kathryn Schmitz is a Distinguished Professor of Public Health Sciences and a Professor of Physical Medicine and Rehabilitation. A trailblazer in the field of Exercise Oncology, she served as the President of the American College of Sports Medicine (ACSM) and founded the Moving Through Cancer initiative.With a PhD in Exercise Physiology, an MPH in Epidemiology, and over 300 peer-reviewed scientific papers, Dr. Schmitz is the foremost voice on the intersection of movement and malignancy. She is the author of the book Moving Through Cancer.Book: Moving Through Cancer by Dr. Kathryn SchmitzInitiative: Moving Through Cancer (ACSM)Research Spotlight: Dr. Rhonda Patrick on Shear Stress & Circulating Tumor CellsReady to put this science into practice? Don't just listen—execute.Join the Longevity Builder Health Lab to access the protocols, community, and tools you need to build a body that lasts.

Featuring perspectives from Dr Kerry Rogers, moderated by Dr Stephen "Fred" Divers, including the following topics:  Chronic Lymphocytic Leukemia (CLL) — Dr Rogers (0:00) Case: A man in his mid 70s with CLL and a history of atrial fibrillation — Dr Lamar (13:08) Case: A fit man in his early 80s with IGHV-unmutated, TP53-mutant symptomatic CLL — Dr Mulherin (21:16) Case: A woman in her mid 80s with IGHV-mutated recurrent CLL who receives pirtobrutinib — Dr Warsch (32:41) Case: A woman in her late 70s with recurrent del(17p) CLL who receives venetoclax/obinutuzumab — Dr Yannucci (44:52) CE information and select publications

Featuring perspectives from Dr Justin F Gainor, Dr Corey J Langer and Dr Misty Dawn Shields, moderated by Dr Stephen "Fred" Divers, including the following topics:  Introduction (0:00) Targeted Therapy for Non-Small Cell Lung Cancer (NSCLC) — Dr Gainor, MD (5:32) Case: A woman in her mid 60s with ALK-mutant metastatic adenocarcinoma of the lung (PD-L1 TPS 70%) — Zanetta S Lamar, MD (17:59) Case: A woman in her mid 80s with EGFR exon 19-deleted adenocarcinoma of the lung with recurrence after 4 years of osimertinib — Jennifer Yannucci, MD (27:53) Case: A woman in her late 60s with HER2-mutant metastatic adenocarcinoma of the lung — Brian P Mulherin, MD (39:41) Case: A man in his early 70s with locally recurrent squamous cell carcinoma of the lung and a MET exon 14 skipping mutation — Sean Warsch, MD (46:39) Case: A woman in her early 70s with ROS1-mutant metastatic adenocarcinoma of the lung that responds to entrectinib and then to pembrolizumab/carboplatin/pemetrexed administered upon disease progression — Dr Yannucci (52:44) Nontargeted Therapy for NSCLC; Small Cell Lung Cancer — Dr Langer (58:16) Neoadjuvant, Perioperative and Adjuvant Anti-PD-1/PD-L1 Antibody-Based Approaches for Patients with Localized NSCLC — Dr Shields (1:14:14) Case: A man in his mid 60s with localized adenocarcinoma of the lung who receives neoadjuvant cisplatin/pemetrexed/pembrolizumab and achieves a pathologic complete response — Dr Mulherin (1:23:19) Case: A man in his early 60s with metastatic mixed adenosquamous NSCLC (PD-L1 TPS 50%) — Sunil Babu, MD (1:30:04) Case: A man in his late 50s diagnosed with extensive-stage small cell lung cancer who receives carboplatin/etoposide/durvalumab — Dr Warsch (1:34:07) CE information and select publications

Dr Kerry A Rogers from The Ohio State University in Columbus summarizes the treatment landscape and reviews relevant clinical datasets for patients with chronic lymphocytic leukemia. CME information and select publications here.

In this episode of the Pediatric and Developmental Pathology, our hosts Dr. Mike Arnold (@MArnold_PedPath) and Dr. Jason Wang speak with Professor Matthew J. Murray of the Department of Pathology and the Department of Paediatric Haematology and Oncology at the University of Cambridge, Cambridge, UK; Consultant Pediatric Pathologist Claire Trayers of the Department of Histopathology at Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; and Consultant Pediatric Oncologist Charlotte Burns of the Department of Paediatric Haematology and Oncology at Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. Hear about how persistence and a serum biomarker for a miRNA helped identify a NUT carcinoma as we talk about their work and their article in Pediatric and Developmental Pathology: Mediastinal NUT Carcinoma With Raised Serum Alpha-Fetoprotein Mimicking a Malignant Germ Cell Tumor: Suspicion Raised Due to Negative Serum miR-371a-3p Levels   Featured public domain music: Summer Pride by Loyalty Freak

Dr Justin F Gainor, Dr Corey J Langer and Dr Misty Dawn Shields summarize the treatment landscape and review relevant clinical datasets for patients with lung cancer.CME information and select publications here.

At the 2025 San Antonio Breast Cancer Symposium, Whitney O'Connor, a two-time breast cancer survivor, licensed professional counselor, and founder of the Boobie Queen Company, presented a poster on the mental health tools she developed to help young women address any mental health and body image challenges they may have. Listen to the episode to hear Whitney explain: the phases of cancer survivorship framework she developed how the retreats her company sponsored used the framework to help young women heal emotionally how she plans to integrate healthcare providers into the framework

Introducing a brand new podcast from ACCC: Oncology Unscripted. In this inaugural episode, hosts Mark Liu and Deirdre Saulet lay out what listeners can expect from the show, including unfiltered, honest dialogue about the state of cancer care today, the most pressing challenges providers are facing, and how they can move forward with hope amid unpredictable headwinds. Liu and Saulet will approach a variety of topics, from operational to financial to clinical, as they explore how providers can help one another, continue to hold important conversations, and act as agents of change in oncology. "I think about my grandmother who spoke Spanish, Chinese, and English...If she was here, and needed to navigate our health care system with a serious illness or diagnosis of cancer, what would that look like for her? I often put my family members in these scenarios...What would they do? What would I do if I was on the other side?...How can we make a complicated health care system work for everyone?" -- Mark Liu, MHA "We can have all the innovations in the world, but if the people who need them most can't access them, what's the point? What are we doing this for?" -- Deirdre Saulet, PhD Mark Liu, MHA Senior Director of Oncology Strategy Transformation & Analytics Mount Sinai Health System Deirdre Saulet, PhD Chief Strategy Officer Jasper Health

Synopsis: This episode is proudly sponsored by Quartzy. What happens when engineering discipline, business pragmatism, and breakthrough immunology collide? In this episode of Biotech 2050, host Alok Tayi sits down with Jay Hartenbach, President & COO of Diakonos Oncology, to unpack one of the most unconventional—and promising—approaches in cancer immunotherapy today. Jay traces his journey from biomedical engineering into biotech operations, sharing how Diakonos was built outside the traditional venture playbook and why the company chose to tackle two of the most punishing cancers first: glioblastoma and pancreatic cancer. He reveals how Diakonos' dual-loading dendritic cell platform creates an exponentially stronger immune response—essentially tricking the body into launching a viral-level attack against cancer. From capital-efficient clinical execution to nontraditional fundraising and early signs of durable patient responses, this conversation offers a rare, behind-the-scenes look at how bold science, disciplined operations, and relentless persistence can reshape what's possible in oncology. Biography: Jay Hartenbach is a distinguished leader in the biotechnology and wellness sectors, known for his passionate commitment to advancing innovative healthcare solutions and transforming patient outcomes. He currently serves as President and Chief Operating Officer at Diakonos Oncology, where he is leading the team through the development and clinical advancement of pioneering immunotherapies targeting some of the most difficult-to-treat cancers, including glioblastoma and pancreatic ductal adenocarcinoma.​ Since joining Diakonos Oncology, Jay has been instrumental in achieving significant milestones such as attaining FDA Fast Track and Orphan Drug Designation for the company's lead candidate, DOC1021, securing greater than $30 million in financing, and establishing research collaborations with leading cancer centers to advance the clinical trials of the company's novel dendritic cell vaccine platform. Before his role at Diakonos, Jay co-founded Medterra, a globally recognized wellness company that set industry standards for quality and innovation, and where he continues to serve as Chairman of the Board, shaping high-level strategic direction. He also co-founded Perland Pharmaceuticals, an early-stage biotech firm focused on developing therapies for arthritis conditions, and has held leadership and board advisory roles across several life sciences ventures.​ Jay holds a degree in biomedical engineering from the University of Miami and a Master of Engineering Management from Duke University, grounding his entrepreneurial leadership with scientific expertise.

What if the biggest gap in cancer care isn't the treatment but what happens before and after? In this episode of ReInvent Healthcare, Dr. Ritamarie Loscalzo is joined by Dr. Nalini Chilkov, founder of the American Institute of Integrative Oncology Research and Education (aiioRE.com), to explore how functional practitioners can fill the urgent void left by conventional oncology.Discover why building a body where cancer cannot thrive is essential, whether your client is recovering from treatment, living with cancer long-term, or wants to prevent recurrence. From terrain restoration and tumor microenvironment to nutrient repletion, blood viscosity, immune modulation, and glycemic control, this episode uncovers clinical strategies every practitioner needs to know to better support cancer patients and survivors.What's Inside This Episode?The distinction between the “disease team” and the “health team” and why both are vitalWhy the tumor microenvironment and terrain may matter more than the tumor itselfThe blood markers that reveal hidden risks that are often missed by oncologistsHow glycemic control and inflammation increase cancer recurrence by up to 40%The often missed danger of fibrin clots in cancer patients (and what to do about it)Why many patients develop autoimmune disease after immunotherapy and how to modulate without overstimulationPractical tips to rebuild the microbiome and blood-brain barrier post-treatmentA new way to think about melatonin, vitamin A, zinc, and omega-3s in cancer supportHow to talk to oncologists and position yourself as an essential part of the care teamWhy terrain restoration and functional support matter most after cancer treatment endsResources and Links:Download our FREE Metabolic Health Guide hereJoin the Next-Level Health Practitioner Facebook group here for free resources and community supportVisit INEMethod.com for advanced practitioner training and tools to elevate your clinical skillsCheck out other podcast episodes hereGuest Resources and LinksVisit OutsmartCancer.com for free recipes, educational tools, and the Outsmart Cancer Roadmap (coming soon)Practitioner training and professional resources at aiioRE.comChilkov Clinic - NaliniChilkov.com Social Media:Facebook: facebook.com/DrNaliniInstagram: instagram.com/drnalinichilkov/LinkedIn: linkedin.com/in/nalinichilkovGuest BioDr. Nalini Chilkov is a leading authority and pioneer in the field of Integrative Cancer Care, cancer prevention, and immune enhancement. She is the Founder of the American Institute of Integrative Oncology Research & Education and creator of the OutSmart Cancer System teaching...

How This Is Building Me, hosted by world-renowned oncologist D. Ross Camidge, MD, PhD, is a podcast focused on the highs and lows, ups and downs of all those involved with cancer, cancer medicine, and cancer science across the full spectrum of life's experiences. In this episode, Dr Camidge sat down with Keith Singer, the founder and executive director of Catch It In Time. Camidge and Singer discussed how Singer's background in broadcasting and cable television has led to a career in promoting cancer awareness. Although Singer initially wanted to be an astronaut, a decline in aerospace engineering jobs during the 1970s and a love for the technical side of high school theater led Singer toward television. He left college early and started his career in Cincinnati, first running a boom microphone and later directing newscasts. Singer explained the career hurdles he faced, noting that they led to opportunities for him to hone his skills and exercise creative freedom. In the mid-1980s, a project involving a new pacemaker sparked Singer's interest in using video for health care education. This fascination led him to co-create an innovative platform that broadcast medical programming for physician continuing medical education. Driven by seeing friends and family struggle with cancer, Singer founded the nonprofit Catch It In Time in 2011. His key communication strategy is that cancer should be the supporting actor, not the lead, allowing stories to appeal to targeted audiences based on their hobbies or professions, with cancer awareness as the secondary message. Catch It In Time is currently developing The User's Guide to Oncology, a software-based program that uses gaming technology to guide patients with lung cancer, providing essential information to help them have better conversations with their care teams. Singer stressed the importance of short video content for garnering views for this type of content. Notably, Catch It In Time recently produced a song titled "Breathe Again" by Lilliana De Los Reyes. "Breathe Again" can be found on all major streaming platforms, and all proceeds are dedicated to cancer awareness and research.

Dr. MaryAnn Wilbur trained her whole life to care for patients, then left medicine behind when it became a machine that punished empathy and rewarded throughput. She didn't burn out. She got out. A gynecologic oncologist, public health researcher, and no-bullshit single mom, MaryAnn walked straight off the cliff her career breadcrumbed her to—and lived to write the book.In this episode, we talk about what happens when doctors are forced to choose between their ethics and their employment, why medicine now operates like a low-resource war zone, and how the system breaks the very people it claims to elevate. We cover moral injury, medical gaslighting, and why she refused to lie on surgical charts just to boost hospital revenue.Her escape plan? Tell the truth, organize the exodus, and build something that actually works. If you've ever wondered why your doctor disappeared, this is your answer. If you're a clinician hiding your own suffering, this is your permission slip.RELATED LINKSMaryAnn Wilbur on LinkedInMedicine ForwardClinician Burnout FoundationThe Doctor Is No Longer In (Book)Suck It Up, Buttercup (Documentary)FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Shefali Kakar, Global Head of PK Sciences and Oncology at Novartis, returns to the AI in Business podcast to discuss how AI is reshaping the earliest and most critical phases of drug development—where strategic investment decisions are made long before a clinical trial begins. Together with Emerj Editorial Director Matthew DeMello, Shefali explores how advanced modeling, in silico design, and patient data are creating a clearer picture of risk and return across R&D portfolios. She explains how pharmaceutical organizations are leveraging multi-factorial models to simulate safety, efficacy, and market potential—down to the molecular level. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the 'AI in Business' podcast!

Changing the Oncology Prior Authorization Story with Exact Sciences This Office Hours will highlight Liz Durkin, Manager of Revenue Cycle as she tells the story of Exact Sciences' journey, from pain points to progress, and provide takeaways for other oncology organizations seeking to change the narrative on prior authorization. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Children can be one of life's greatest blessings. Breast cancer survivors Alex Miles-Stiffler and Sara Galher-Barlow long for larger families but their diagnoses put those dreams farther and farther out of reach. Alex struggled to start a family before her diagnosis. The heart ache she felt after two miscarriages was unbearable at times, and her fertility challenges only grew after breast cancer treatment, but she wasn't giving up on the family she dreamed of having. Sara always knew she wanted several children. She was blessed with a precious daughter prior to being diagnosed, but her cancer was aggressive and treatment couldn't wait. She had to forego egg preservation, and the uncertainty of fertility along with the cost of fertility treatments will make it harder to grow her family.

Episode 5 of Standard Deviation with Oliver Bogler on the Out of Patients podcast feed pulls you straight into the story of Dr Ethan Moitra, a psychologist who fights for LGBTQ mental health while the system throws every obstacle it can find at him.Ethan built a study that tracked how COVID 19 tore through an already vulnerable community. He secured an NIH grant. He built a team. He reached 180 participants. Then he opened an email on a Saturday and learned that Washington had erased his work with one sentence about taxpayer priorities. The funding vanished. The timeline collapsed. His team scattered. Participants who trusted him sat in limbo.A federal court eventually forced the government to reinstate the grant, but the damage stayed baked into the process. Ethan had to push through months of paperwork while his university kept the original deadline as if the shutdown had not happened. The system handed him a win that felt like a warning.I brought Ethan on because his story shows how politics reaches into science and punishes the people who serve communities already carrying too much trauma. His honesty lands hard because he names the fear now spreading across academia and how young scientists question whether they can afford to care about the wrong population.You will hear what this ordeal did to him, what it cost his team, and why he refuses to walk away.RELATED LINKSFaculty PageNIH Grant DetailsScientific PresentationBoston Globe CoverageFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.